Theradaptive develops a drug delivery and research platform. The company's platform converts recombinant proteins into material-binding variants that can be used to coat implants, devices, and injectable carriers for vascular, soft tissue, and orthopedic repair. The company was founded in 2017 and is based in Frederick, Maryland.
Theradaptive's Products & Differentiators
Osteoinductive bone implant that has rhBMP bound to it for persistent, precise delivery
Expert Collections containing Theradaptive
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Theradaptive is included in 1 Expert Collection, including Early-Stage Pharma Market Map.
Early-Stage Pharma Market Map
Theradaptive has filed 8 patents.
Biological warfare, Beta blockers, Biological warfare facilities, Bioterrorism, Biological hazards
Biological warfare, Beta blockers, Biological warfare facilities, Bioterrorism, Biological hazards
Latest Theradaptive News
Oct 4, 2023
Since his days as a Cadet at West Point and then as a U.S. Army Officer on the fields of battle in Iraq, Luis Alvarez, chief executive officer of the Frederick, Maryland-based regenerative medicine company Theradaptive, has trained to be a leader. By Alex Keown | October 4, 2023 BioBuzz’s mission is simple: to be more connected. Our regionally-focused storytelling, programs, events and experiences connect, amplify and create impact across the life science workforce in growing biohubs. We greatly appreciate your support as a small startup and ask that you SUBSCRIBE to our weekly newsletters, FOLLOW us on LinkedIn or work with us . Long before Theradaptive Chief Executive Officer stepped into the world of the c-suite, Luis Alvarez prepared for his role at West Point. As a cadet at the military institute, and as a former officer in the United States Army, leadership has become ingrained in the very fabric of Alvarez’s being. Leadership Lessons From the Military Alvarez discusses his journey with BioBuzz and emphasizes several aspects of leadership that he works to embody in order to find success, including; preparation, team, humility, mission, and commitment. “The entire curriculum [at West Point] is centered around leadership development,” explained Alvarez, who later earned a Ph.D. in Biological Engineering from MIT where his research focused on bone and tissue regeneration. The lessons he learned as a cadet at the academy were later put to the test in the Army, where he developed strategies and best practices to guide his men through various challenges and obstacles that the military required. That included a combat tour in Iraq, a tour that laid the groundwork for Theradaptive. Following that, Alvarez shifted to the Department of Defense. There, he was the co-founding Deputy Director of the Department of Defense Regenerative Medicine program. In that role, he led various teams focused on biological research. He led the department’s largest recombinant biologics program through mid-stage clinical testing. Alvarez said his work at the Department of Defense provided him with insights into the world of running a biopharma company. He learned how to navigate regulatory pathways, as well as the lifecycle of a clinical program. So much of what he did was applicable to a private sector company, he said. “That experience gave me the understanding about working with people who are smarter than I am,” Alvarez said. “I think if you’re the smartest person in the room, then you’re in the wrong room. The most important part of leadership is building a good team… orient that team on a mission… and then get out of their way.” The Birth of Theradaptive: Answering A Critical Question That mission is critically important to Alvarez and the Theradaptive team is developing a regenerative medicine asset that can support the regeneration of native bone tissue. In the theater of war, Alvarez saw some of his soldiers suffer significant extremity wounds. Imagining solutions to alleviate their suffering led to the founding of Frederick-based Theradaptive. In part, the company was formed in 2016 to answer the question as to why so many members of the armed forces who returned from combat underwent delayed amputations weeks or months after the initial injury. Theradaptive’s answer to that question was the development of a transformational regenerative technology, AMP2. Theradaptive’s lead regenerative medicine AMP2 technology is a proprietary variant of BMP2, a bone inducing protein that regenerates bone tissue. AMP2, which has secured multiple breakthrough designations from the FDA, was licensed from the U.S. Department of Defense U.S. Army Medical Research & Development Command. The company’s asset is applied to implanted medical devices with the goal for a more precise and safer method for regenerating native bone tissue. AMP2 has beaten the standard of care in every preclinical study conducted to date, Alvarez said. Now, that data will be tested in humans. The company is taking AMP2 into a Phase I/II study. Alvarez credits the Theradaptive team for the progress the company is making with AMP2. The company stayed focused on the mission of taking AMP2 into human trials and succeeded in that goal. As a company leader, Alvarez said it’s important to listen to the experts within Theradaptive, collect the data necessary to make a decision and then act on that. It’s also important for a leader to know when to step away for a while in order to rest and recharge. As a lover of all things beach-related, from sailing to seafood, Alvarez said it’s critical for his own mental health to truly take time off from the company. That means he truly disconnects. When he is on vacation, Alvarez said he turns off his phone and doesn’t look at his emails. “You have to give yourself time to think and breathe and read. You need to take advantage of the time and disconnect. Your vacation time is as valuable to the company as your working time, you need to be refreshed and recharged,” he said. Being fully rested will be important when Theradaptive shifts into a clinical stage regenerative medicine company. Advancing into clinical trials will require additional funding for Theradaptive. After closing a $26 million Series A financial round earlier this year, Alvarez said they will begin the process for a Series B round in early 2024. Although current economic conditions have reduced the amount of investing compared to previous years, Alvarez said he believes there is a significant amount of available capital “waiting on the sidelines.” He said the company will be “extra diligent” when going into its next fundraising phase and plans to work with strategic investors, including the Maryland Stem Cell Research Commission, a division of TEDCO , which provided grant funding to Theradaptive earlier this year. Theradaptive was also just awarded a U.S. Department of Defense (DOD) Clinical Trial Award of up to $7.4M with options, subject to FDA approval to begin phase I/II clinical studies. “We are deeply committed to solving this important problem for service members who suffered traumatic injuries and are grateful for those who support that mission,” Alvarez said. About the Author
Theradaptive Frequently Asked Questions (FAQ)
When was Theradaptive founded?
Theradaptive was founded in 2017.
Where is Theradaptive's headquarters?
Theradaptive's headquarters is located at 5350 Partners Court, Frederick.
What is Theradaptive's latest funding round?
Theradaptive's latest funding round is Grant - IV.
How much did Theradaptive raise?
Theradaptive raised a total of $36.2M.
Who are the investors of Theradaptive?
Investors of Theradaptive include U.S. Department of Defense, Maryland Stem Cell Research Fund, AMP Squared Capital Partners, Maryland Venture Fund, ORTHOReBIRTH and 3 more.
Who are Theradaptive's competitors?
Competitors of Theradaptive include Medtronic.
What products does Theradaptive offer?
Theradaptive's products include OsteoAdapt.
Compare Theradaptive to Competitors
LimiFlex develops a medical stabilization system designed to treat degenerative lumbar spinal disorders. It caters to patients suffering from degenerative spondylolisthesis (DS). The company was founded in 2015 and is based in San Carlos, California.
Medivis offers a surgical augmented reality (AR) technology platform for surgical applications. It offers solutions such as cranial navigation, spine navigation, body navigation among others. The company was founded in 2016 and is based in New York, New York.
OxyPrem provides sensors and solutions for patients suffering from brain damage. Its medical silicon device monitors the oxygen levels of preterm infants' brains using non-invasive near-infrared light. The company was founded in 2018 and is based in Zurich, Switzerland.
Path Keeper provides a three-dimensional (3D) camera system delivering real-time navigation in spine surgeries. Its system tracks surgical tools and the patient's anatomy independently in 3D imaging, guiding accurate device positioning and implantation. It was formerly known as Deep Health. It was founded in 2018 and is based in Kfar Saba, Israel.
Diabetes Neuromathix is an AI/Medtech startup building genuinely machine-intelligent artificial pancreas software suitable for the people who need it most: people with 'brittle' type-1 diabetes (T1D), who suffer from large-scale swings in blood glucose levels on a daily basis.
Theromics develops a thermal accelerant technology for soft tissue ablation procedures and combination therapy. Its proprietary HeatSYNC gel is based on a protein naturally found in the body used to combine thermal ablations of soft tissue with drug delivery. HeatSYNC is used during microwave and radiofrequency ablations of cancerous tumors. The company was founded in 2016 and is based in West Bridgewater, Massachusetts.